Biomea Fusion is a clinical-stage biotechnology company focused on developing differentiated oral small molecule therapies designed to address the underlying biology of metabolic disease. Our goal is to move beyond chronic symptom management and advance therapies with the potential to deliver durable, meaningful clinical benefit for patients.
Our pipeline includes two differentiated oral development programs:
- Icovamenib, a potential first-in-class oral menin-targeted therapy being developed for diabetes
- BMF-650, a next-generation oral GLP-1 receptor agonist designed to optimize exposure, convenience, and tolerability for the treatment of obesity and related metabolic disorders
Biomea retains worldwide rights to all of its programs and is advancing multiple clinical studies, with key milestones and data readouts anticipated in 2026.
At Biomea, our mission is to transform the treatment landscape for serious metabolic diseases through innovative science and precision drug design. We leverage deep expertise in covalent chemistry, biology, and clinical development to discover and develop novel small molecule therapies that target key drivers of disease progression.
All of our molecules are discovered and developed in-house using our proprietary drug discovery capabilities. Our research and development team is actively engaged across every stage of the development process, from target identification and molecular design through preclinical and clinical development, with the goal of delivering highly selective therapies that have the potential to improve patients’ lives.